Immuneering Corporation to Present at Major Healthcare Conference
Immuneering Corporation, a progressive clinical-stage oncology company, is gearing up to present at the highly anticipated Piper Sandler 36th Annual Healthcare Conference. This event, which focuses on advancements in health and medicine, is taking place at the luxurious Lotte New York Palace. Immuneering is particularly excited about this opportunity, as it allows them to connect with other industry leaders and showcase their innovative approaches to cancer treatment.
Leadership Team Participation
The leadership team representing Immuneering includes Ben Zeskind, the Chief Executive Officer, alongside Harold "E.B." Brakewood as the Chief Business Officer and Mallory Morales, CPA, who serves as the Chief Accounting Officer and Treasurer. Together, they will discuss the company’s promising pipeline, unique platform, and comprehensive business strategy aimed at revolutionizing cancer therapies.
Format of the Presentation
The format of the presentation will be a Fireside Chat, complemented by individual meetings with investors. This setup provides an informal yet insightful environment for discussion, encouraging engagement, and fostering relationships between the Immuneering team and potential investors.
Scheduled Presentation Details
Immuneering's session is set for December 5, during which they will present from 1:00 PM to 1:25 PM ET. An intriguing aspect of this presentation is that it will be webcast live, allowing a broader audience to gain insights into their innovative work and future plans.
Webcast Details
For those unable to attend in person, the presentations will also be archived for access later. The webcast will be available in the Investor Relations section of Immuneering’s website, ensuring that investors and interested parties can stay informed about the company’s latest developments.
About Immuneering Corporation
Immuneering Corporation is dedicated to developing groundbreaking treatments targeting RAS and RAF signaling pathways, which are integral to many cancer types. Their main goal is to develop therapies that are universally effective, addressing the need for more inclusive and impactful cancer treatments.
Pipeline Overview
Immuneering’s lead product candidate, IMM-1-104, is currently in a Phase 2a clinical trial aimed at patients suffering from advanced solid tumors that include RAS mutations. Additionally, they are advancing another promising compound, IMM-6-415, into a Phase 1/2a trial. These initiatives reflect their commitment to pushing the boundaries of cancer therapy.
Ongoing Commitment to Innovation
In addition to their current trials, Immuneering is actively engaged in several earlier-stage programs that hold great potential for the future of oncology. Their efforts center around a strategic vision of harnessing Deep Cyclic Inhibition to affect cancerous cells while preserving healthy tissues, distinguishing their approach in the biotech industry.
Connecting with Stakeholders
Immuneering Corporation believes in the importance of communication and transparency with stakeholders, including investors and the public. Their ongoing updates and presentations are key to fostering trust and collaboration. For media inquiries, Gina Nugent can be reached at gina@nugentcommunications.com, while investor relations are managed by Laurence Watts at 619-916-7620.
Frequently Asked Questions
What is the Piper Sandler Healthcare Conference?
The Piper Sandler Healthcare Conference is an annual event that brings together key players in the healthcare industry to discuss innovations and share insights.
When is Immuneering presenting at the conference?
Immuneering is scheduled to present on December 5 from 1:00 PM to 1:25 PM ET.
What is Immuneering's main focus?
Immuneering Corporation focuses on developing universal-RAS/RAF medicines for cancer patients, aiming for broadly effective treatments.
Who from Immuneering will be presenting?
Ben Zeskind, Harold "E.B." Brakewood, and Mallory Morales will represent Immuneering during their presentation.
How can I access the presentation?
The presentation will be webcast live and archived on Immuneering’s Investor Relations website for later viewing.
